63418 JAK3/TEC kinase pathways are active in alopecia areata lesions, and their inhibition with Ritlecitinib prevents αCD3/αCD28+IL-2 induced immune privilege collapse in healthy hair follicles ex vivo

The study investigates the role of JAK3/TEC kinase pathways in alopecia areata lesions and evaluates the efficacy of Ritlecitinib, a JAK inhibitor, in preventing immune privilege collapse in healthy hair follicles. The research demonstrates that these pathways are active in alopecia areata and that Ritlecitinib effectively inhibits the αCD3/αCD28+IL-2 induced collapse of immune privilege in hair follicles ex vivo. This suggests that targeting these pathways with Ritlecitinib could be a promising therapeutic approach for treating alopecia areata.